Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here! Here! Time for me to jump back in. Took a small profit to offset some losses during the last bump...I smell .00s again real soon...
Doing a little digging but unfortunately I do not have the right connections for lawyers who handle this side of the law.
Admitting you have a problem is the first step....
Hi my name is Thomas and I am an inept CEO....
He already received $6000 of "My Help"
Can you use the word CEO to describe yourself when you have no product, no employees, no revenue, no business model at all?
Roar!!!
MMX!!!
$ENTI = SCAM
Still looking into legal action
ROAR - how's that going?
MOASS any day now
$ENTI = NO$
Nabbbss you forgot IMO
Thank You
Little behind on my reading so I have to do some research on this one.
It looks promising however.
What's the name of the game? This was trading in the 2s (Actually in the 6s until March) for over a year and then tanked at the end of June. How is that Big Fish loading on a News Day? I am not invested here but was watching. I could care less that you sold at 1.40 when up until 16 days ago this was over 2.00.....Just curious as to why it took the dive
Its been 10 month's people and still no divy
Ironically ENTI and PTEL are not even registered with FINRA
but FINRA approved this Stock Dividend 10 months ago?
FINRA Approves 12 Billion Stock Dividend to Encounter Technologies (ENTI) Shareholders
Date : 09/21/2011 @ 7:00AM
Source : PR Newswire
Stock : Encounter Techs (PN) (ENTI)
Quote : 0.0001 0.0 (0.00%) @ 5:32AM
FINRA Approves 12 Billion Stock Dividend to Encounter Technologies (ENTI) Shareholders
Tweet
Print
Alert
Encounter Techs (PN) (USOTC:ENTI)
Historical Stock Chart
1 Year : From Jul 2011 to Jul 2012
Click Here for more Encounter Techs (PN) Charts.
Encounter Technologies, Inc. (ENTI:PK), a company specializing in social media, video technology and on-line entertainment solutions, announced today final FINRA approval for a special dividend of preferred shares of Pegasus Tel (PTEL:OTCBB). On June 10, 2011 (Official Record Date), all common stock shareholders of Encounter Technologies became entitled to one (1) share of Pegasus Tel (PTEL) for each share of ENTI they own. The revised payable date for the dividend is October 3, 2011(Official Payable Date).
"I am pleased we are finally through the approval process," stated Thomas Hargis, CEO of Encounter Technologies. "This means we can really focus on our new social networking tool Roar! as well as some of our other platform innovations. This is a new and exciting time over here at Encounter. We are also looking forward to watching PTEL and MusicMatrix start to take off now too."
On March 30, 2011, Anthony DiBiase was named CEO for Pegasus Tel, Inc. and as a result, he declared a one-for-one dividend for ENTI Shareholders. As part of an asset purchase agreement with Pegasus Tel, Encounter Technologies received preferred shares of Pegasus. These preferred shares will be distributed to Encounter shareholders sufficient to allow each shareholder, once converted to Pegasus common stock, to have the same number of common shares of Pegasus as they hold in Encounter. The MusicMatrix web site was acquired by Pegasus Tel from Encounter Technologies in exchange for these preferred shares of PTEL.
"My shareholders know it has always been my mission to reward them for their continued support of MusicMatrix," stated Pegasus CEO Anthony DiBiase. "This dividend with PTEL is the most effective way to accomplish that goal and gain further investor credibility for our business. It is with sincere pleasure that I officially welcome over 3,000 new shareholders to Pegasus Tel from Encounter Technologies."
ABOUT ENCOUNTER TECHNOLOGIES, INC. (ENTI:PK)
Encounter Technologies, Inc. specializes in social media, video technology and on-line entertainment web solutions. The Company utilizes pre-built applications to provide platforms for businesses interested in utilizing video technology to increase online collaboration and interaction. The goal is to provide clients with the best methods to increase user value and achieve desired business results. Simply put, Encounter Technologies, Inc. transforms ideas into revenues. For more information about Encounter Technologies, Inc. visit www.encounterdt.com
ABOUT PEGASUS TEL, INC. (PTEL:OTCBB)
Pegasus Tel, Inc. is a global leader in web based technology solutions and corporate headquarters of MusicMatrix.com. The primary goal of the Company's projects is focusing on constant innovation in emerging technology areas. We believe that our corporate partners will get only the best when they work with us. PTEL web based projects engage users with the core features of everyday life through innovative video streaming, web-based and mobile applications. We market and refine products from emerging technologies like mobile and social media, which enable our users to stay in 'constant connection' with their users through relevant and unique online marketing initiatives. Our solutions allow customers, employees, constituents, and shareholders to engage, communicate, connect and grow with others that share similar interests. Whether you are using a smartphone, a computer, or a tablet, PTEL's technology and platforms provide you with the optimal experience that you are looking for in an online platform. For more information on Pegasus Tel, please visit www.ptelcorp.com.
INVESTOR RELATIONS CONTACT: info@encounterdt.com
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place under reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Encounter Technologies, Inc. undertake no obligation to update such statements.
SOURCE Encounter Technologies, Inc.
Can anyone explain why the nose dive at the beginning of the month?
New to this one.
Thanks
When are we starting legal action?
These guys need to go to jail - ALL of them
http://ih.advfn.com/p.php?pid=nmona&article=49252265
MOASS
Here it comes.....
Go $ENTI
.0096.....I bought in 001s and didnt sell at .0096....
UGH!!!
Many of the locally charged parties were company presidents, or held similar positions. Aside from those mentioned above, Douglas Hague (president of Clean Coal Technologies) and 42-year-old Ryan Coblin (who presided over Delivery Technology Services) were also indicted. According to the press release, Coblin was arrested in September of last year for attempting to bribe a hedge fund fiduciary in an attempt to purchase overpriced stock using hedge fund money. Coblin reportedly pled guilty to the charges in March. Hague, on the other hand, was charged just days ago, on June 1, with the almost identical crime of bribing a fiduciary in order to induce the purchase of overpriced stock. Hague does not appear to have commented publicly on the incident.
Here Here!!!
The Working Man is a sucker....I work 7 days a week at 3 jobs I should know....
To the person calling out the longs - Why beat a dead horse?
We went down with a sinking ship.
See you in 18 months when HNSS get pumped again.
Usually when they have to PR something a second time before its released its the final pump before the dump starts. Take some profits people.
Question What makes an Opinion Honest?
Can you also have a Dis-Honest Opinion?
$SEEK
Been a way for a while - WTF is going on?
I really liked SG and thought this had traction as a company
This stock is a POS?
Grant it having stock in PTEL and/or ENTI is currently worthless but to flat out lie about this Divy and the shenanigans that went on during the forward stock split that locked all our shares while the PPS went to .002 is borderline criminal in my opinion. Also the fact that both companies have played revolving CEOs during this time cries out SCAM.
Now I am starting to get Mad.....
That's funny because the "sale" of MMX was rescinded....
Has anyone looked at a class action lawsuit against ENTI/PTEL for the outright lies that were perpetrated in this fake sale of MMX?
Any lawyers out there?
Anyone ever get their PTEL shares?
lolololollolololol
A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Naus...
Date : 06/29/2012 @ 8:00AM
Source : Business Wire
Stock : AP Pharma (APPA)
Quote :0.74 0.005 (0.68%) @ 9:42AM
A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Naus...
Tweet
Print
Alert
AP Pharma (OTCBB:APPA)
Historical Stock Chart
1 Month : From Jun 2012 to Jul 2012
Click Here for more AP Pharma Charts.
A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced additional data from the Company’s Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV). The findings from the analysis of this subset of data indicate that APF530 offered comparable nausea control and patient satisfaction to palonosetron (Aloxi®) over a 5-day period. The Company presented the study results today at a poster presentation during the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) International Symposium in New York. As previously reported, the Phase 3 study showed APF530 was comparable to palonosetron in preventing both acute- and delayed-onset CINV in patients receiving either moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC).
“Delayed-onset nausea and vomiting remains a major issue associated with many cancer treatment options, which can affect a patient’s quality of life as well as his or her ability to sustain the recommended potentially lifesaving chemotherapy regimen,” said Rebecca A. Clark-Snow, RN, BSN, OCN, clinical nurse coordinator and chair of the MASCC Antiemetic Study Group. “In particular, patients who have experienced nausea and vomiting during previous chemotherapy treatments are more susceptible to experiencing a recurrence during subsequent therapy. These data indicate that APF530 has the potential to be a promising therapy option for physicians and patients.”
Study Results
The study found patient satisfaction between patients administered APF530 and palonosetron to prevent CINV following MEC or HEC were comparable, with no statistically significant differences. The severity of nausea experienced by patients in the study was also comparable with no statistically significant differences. These findings held for subgroups of patients regardless of whether, or not, they had previously received chemotherapy treatment. The study also showed that for each day of a 5-day period there were no statistically significant differences between APF530 and palonosetron in patient satisfaction and severity of nausea.
“These data indicate that APF530 has the potential to provide both comparable antiemetic effects and patient satisfaction results to palonosetron,” said John Whelan, A.P. Pharma’s president and chief executive officer. “Our continued analysis of the Phase 3 study further demonstrates the potential role APF530 could play as a new therapeutic agent in cancer care.”
Study Design
A.P. Pharma’s pivotal Phase 3 clinical trial was a multicenter, randomized, observer-blind, actively-controlled, double-dummy, parallel group study that compared the efficacy of APF530 with palonosetron. The trial stratified patients into two groups, one receiving moderately and the other receiving highly emetogenic chemotherapeutic agents in accordance with the Hesketh algorithm, which assigns emetogenic levels based on the chemotherapy agent, drug dosage and combinations employed. In each group, the patients were randomized to receive in the first chemotherapy treatment cycle either APF530 high dose (10 mg granisetron), APF530 low dose (5 mg granisetron) or the currently approved dose of palonosetron. Patients used a daily diary to record severity of nausea, vomiting/retching episodes, use of rescue medication, and satisfaction with nausea/vomiting control over a 5-day period following chemotherapy.
About CINV
Prevention and control of nausea and vomiting, or emesis, are very important in the treatment of cancer patients. The majority of patients receiving chemotherapy will experience some degree of emesis if not prevented with an antiemetic, typically administered just prior to chemotherapy.
Chemotherapy treatments can be classified as moderately emetogenic, meaning that 30% to 90% of patients experience CINV, or highly emetogenic, meaning that more than 90% of patients experience CINV, if they do not receive an antiemetic. Acute-onset CINV occurs within the first 24 hours following chemotherapy treatment. Delayed-onset CINV occurs more than 24 hours after treatment and may persist for several days. Prevention of CINV is important because the distress caused by CINV can severely disrupt patient quality of life and can lead some patients to delay or discontinue chemotherapy.
About APF530
A.P. Pharma's lead product, APF530, is in development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company’s proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company’s primary focus is on its lead product, APF530, for the prevention of CINV. A.P. Pharma received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012. The Company has additional research and development programs that utilize its bioerodible, injectable and implantable delivery systems. For further information, please visit the Company's web site at www.appharma.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with capital resources and liquidity, timely development and regulatory approval of product candidates, satisfactory completion of clinical studies, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.
Just find it fishy to announce news on a product that isnt even working yet. But thats penny land for you.
Let's hope we can login to the site within a week or two
Am I missing something I cannot even register on the website?
So I kept buying HNSS as it went up to 1.5 cents...
So why didnt I sell on the way down?
Its a choice between Stupidity and Greed.....
Yes TDA did acknowledge the share distribution as well however are blaming the DTC for not distributing the shares yet. It appears Scottrade and Ztrade front the shares to their customers before waiting for them to clear DTC hence why these account holders see them already.
Hello Hello Helllo Helo.....
Plus 50%!!!
We will see a penny by June!!
Very Frustrating
Mr Black - Make it all better!!!!!
$HNSS
I am however disappointed in their last PR when they said because of the DTC they do not have the $$$ to BUILD their Microfill machine....so what the $%#$% were they going to the Expo for to show pictures of it??? I was under the impression it was built and needed "modifications".
Lost past tense
Its only money
I am also Long and Strong
Stupid is as Stupid does....
I thought I was buying a fruit company.....
You need both Bo
Wow you need a hug bro
Whoever sells this low just aint right in the head